Ann Dermatol.  2014 Apr;26(2):172-176. 10.5021/ad.2014.26.2.172.

Intralesional Methotrexate for the Treatment of Keratoacanthoma: Retrospective Study and Review of the Korean Literature

• Yoo MG
• Kim IH

• KMID: 2171651
• DOI: http://doi.org/10.5021/ad.2014.26.2.172

Abstract

BACKGROUND
Although intralesional methotrexate (MTX) is an effective, nonsurgical treatment of keratoacanthoma (KA), there have not been many reports of on the MTX treatment for KA in Korea.
OBJECTIVE
The purpose of this study was to evaluate the clinical efficacy of the intralesional MTX for the treatment of KA in Korean patients.
METHODS
We retrospectively studied seven patients with KA who received intralesional injection of MTX in our department. The efficacy was evaluated based on the physician assessment. Our review also included the cases of KA treated with intralesional MTX in Korean patients from the previous reports. We then analyzed the therapeutic regimens in the Korean patients by comparing them with the Caucasian patients.
RESULTS
We identified 11 cases of Korean KA patients treated with an intralesional MTX, including seven from our institution and four from the Korean literature. Ten of the 11 patients (91%) showed a complete resolution with an intralesional MTX. No adverse events were observed during the treatment and the follow-up periods. No recurrence was found during the follow-up. In therapeutic analysis, the Korean patients required 2 to 7 injections (mean 4.6 injections) to achieve a tumor resolution with the mean time to clearing at 7.6 weeks.
CONCLUSION
Intralesional MTX can be an effective and safe non-operative treatment modality for most Koreans with KA.

Keyword

Intralesional injection; Keratoacanthoma; Koreans; Methotrexate

MeSH Terms

Asian Continental Ancestry Group
Follow-Up Studies
Humans
Injections, Intralesional
Keratoacanthoma*
Korea
Methotrexate*
Recurrence
Retrospective Studies*
Methotrexate

Figure

• 

  Fig. 1 Treatment course summary for tumor (patient 4). (A) Appearance of tumor on right side of nose prior to treatment. (B) Appearance of tumor 4 weeks after start of treatment. (C) Appearance of tumor 12 weeks after start of treatment (total of six methotrexate injections), with minimal atrophic scar evident.

Reference

1. Beham A, Regauer S, Soyer HP, Beham-Schmid C. Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol. 1998; 5:269–280.

2. Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg. 2004; 30:326–333. discussion 333.

3. Kim CY, Yoon TJ, Kim TH. Treatment of keratoacanthomas with intralesional 5-fluorouracil and methotrexate. Korean J Dermatol. 2001; 39:1175–1178.

4. You DO, Youn NH, Park SD. Successful treatment of two cases of keratoacanthomas with intralesional methotrexate. Korean J Dermatol. 2002; 40:555–558.

5. Hong HS, Ahn H, Eom JW. A case of giant keratoacanthoma of the lower lip treated with intralesional methotrexate. Korean J Otolaryngol-Head Neck Surg. 1997; 40:1858–1862.

6. Shin JB, Cho HM, Park JH, Son SW, Kim IH. Two cases of giant keratoacanthoma treated with intralesional methotrexate. Korean J Dermatol. 2006; 44:902–905.

7. Melton JL, Nelson BR, Stough DB, Brown MD, Swanson NA, Johnson TM. Treatment of keratoacanthomas with intralesional methotrexate. J Am Acad Dermatol. 1991; 25:1017–1023.

8. Stranc MF, Robertson GA. Conservative treatment of keratoacanthoma. Ann Plast Surg. 1979; 2:525–530.

9. Schwartz RA. The keratoacanthoma: a review. J Surg Oncol. 1979; 12:305–317.

10. Annest NM, VanBeek MJ, Arpey CJ, Whitaker DC. Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature. J Am Acad Dermatol. 2007; 56:989–993.

11. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol. 1991; 25:306–318.

12. Parker CM, Hanke CW. Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil. J Am Acad Dermatol. 1986; 14:770–777.

13. Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol. 2010; 63:689–702.

14. Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol. 2011; 64:413–422.

15. Cohen PR, Schulze KE, Nelson BR. Pancytopenia after a single intradermal infiltration of methotrexate. J Drugs Dermatol. 2005; 4:648–651.

16. Goebeler M, Lurz C, Kolve-Goebeler ME, Bröcker EB. Pancytopenia after treatment of keratoacanthoma by single lesional methotrexate infiltration. Arch Dermatol. 2001; 137:1104–1105.